Schäffer J, Karg C, Piepenbrock S
Abteilung Anästhesiologie II, Medizinische Hochschule Hannover.
Anaesthesist. 1994 Nov;43(11):723-9. doi: 10.1007/s001010050114.
In addition to laryngoscopy, endotracheal intubation, and other stressful intraoperative phases, hypertension occurs during recovery from anaesthesia, provoking post-operative complications like bleeding and increased intracranial or intraocular pressure. Furthermore, these hypertensive reactions result in life-threatening complications, especially in patients with pre-existing cardiovascular diseases. In this study, the effect of the new, short-acting beta-blocker esmolol given as a single bolus for preventing the increases in blood pressure and heart rate during recovery from anaesthesia and extubation in patients with hypertension was investigated. PATIENTS AND METHODS. Sixty-three patients with a history of hypertension over a period of more than 6 months and blood pressure (BP) more than 150/90 mm Hg undergoing intervertebral-disc, otolaryngologic, or eye surgery were included in the study. The operations were performed during thiopentone-induced isoflurane anaesthesia with relaxation by atracurium. The patients were assigned to three groups after giving witnessed oral informed consent. During the study period they received the study drug twice: (A) 30-90 s before turning off the nitrous oxide; and (B) 20-90 s before extubation. Group I (placebo) received placebo each time, group II (100 mg esmolol) placebo at A and 100 mg esmolol i.v. at B, and group III (200 mg esmolol) 100 mg esmolol i.v. each time. After each medication the cardiovascular parameters were measured noninvasively over a period of 10 min every minute and in the following 2 h every 15 min. RESULTS. After the first medication systolic and diastolic BP, heart rate (HR), and rate-pressure product (RPP) were lower in patients receiving 100 mg esmolol (Group III) than in groups I and II. After the second injection the blood pressure was lower in the two groups receiving 100 mg esmolol, than the placebo group (I: 180.1 +/- 7.4/100.7 +/- 3.6; II: 152.8 +/- 5.8/87.9 +/- 3.4; III: 157.9 +/- 5.3/91.5 +/- 3.6 mm Hg [mean 2 min +/- SEM]). The changes in HR (I: 88.2 +/- 3.8; II: 75.6 +/- 2.6; III: 72 +/- 3.1 min-1) and RPP (I: 15,800 +/- 900; II: 11,700 +/- 700; III: 11,400 +/- 600) were similar. In 8 of the 20 patients in group III the HR dropped below 60.min-1, but in none of these patients did the BP become instable. CONCLUSIONS. The sympathoadrenergic reaction during recovery from anaesthesia and extubation can be treated by beta-blocking agents, but such therapy is not without risk because of the long half-life and effects of the therapy on other factors such as postoperative loss of intravascular volume. Esmolol is a new, short-acting, cardioselective beta-blocker with a very short plasma distribution time and a elimination half-life of 9.2 min. Thus, the potential risks of beta-blockers due to half-life are minimised. The results of this study show that a dangerous increase in BP and HR with increased myocardial oxygen consumption can be prevented by a single bolus, and better by a double bolus of 100 mg esmolol. Although bradycardia with HR below 50.min-1 in 8 patients might indicate a risk of cardiac instability, the systolic BP did not fall below 100 mm Hg, and the episode of bradycardia was so short that there was no risk to the patients.
除喉镜检查、气管内插管及其他术中应激阶段外,高血压还会在麻醉苏醒期出现,引发术后并发症,如出血及颅内或眼内压升高。此外,这些高血压反应会导致危及生命的并发症,尤其是在已有心血管疾病的患者中。在本研究中,调查了新型短效β受体阻滞剂艾司洛尔单次推注对预防高血压患者麻醉苏醒及拔管期间血压和心率升高的效果。患者与方法。63例有超过6个月高血压病史且血压(BP)高于150/90 mmHg的患者纳入研究,他们接受椎间盘、耳鼻喉或眼科手术。手术在硫喷妥钠诱导的异氟烷麻醉及阿曲库铵松弛作用下进行。在获得见证的口头知情同意后,将患者分为三组。在研究期间,他们两次接受研究药物:(A)在关闭氧化亚氮前30 - 90秒;(B)在拔管前20 - 90秒。I组(安慰剂组)每次均接受安慰剂,II组(100 mg艾司洛尔组)在A时接受安慰剂,在B时静脉注射100 mg艾司洛尔,III组(200 mg艾司洛尔组)每次静脉注射100 mg艾司洛尔。每次用药后,在10分钟内每分钟无创测量心血管参数,随后2小时每15分钟测量一次。结果。首次用药后,接受100 mg艾司洛尔的患者(III组)收缩压、舒张压、心率(HR)及率压积(RPP)低于I组和II组。第二次注射后,接受100 mg艾司洛尔的两组血压低于安慰剂组(I组:180.1±7.4/100.7±3.6;II组:152.8±5.8/87.9±3.4;III组:157.9±5.3/91.5±3.6 mmHg[平均2分钟±标准误])。HR(I组:88.2±3.8;II组:75.6±2.6;III组:72±3.1次/分钟)及RPP(I组:15,800±900;II组:11,700±700;III组:11,400±600)的变化相似。III组20例患者中有8例HR降至60次/分钟以下,但这些患者中无一例血压不稳定。结论。麻醉苏醒及拔管期间的交感肾上腺素能反应可用β受体阻滞剂治疗,但由于该疗法半衰期长且对其他因素如术后血管内容量丢失有影响,并非没有风险。艾司洛尔是一种新型短效、心脏选择性β受体阻滞剂,血浆分布时间极短,消除半衰期为9.2分钟。因此,因半衰期导致的β受体阻滞剂潜在风险降至最低。本研究结果表明,单次推注,尤其是100 mg艾司洛尔双次推注可预防BP和HR危险升高及心肌氧耗增加。尽管8例患者出现HR低于50次/分钟的心动过缓可能提示心脏不稳定风险,但收缩压未降至100 mmHg以下,且心动过缓发作时间很短,对患者无风险。